Cell donor’s socioeconomic status shapes cancer treatment outcomes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The socioeconomic status of cell donors affects the health outcomes of blood cancer patients who underwent hematopoietic cell transplantation, according to a new study led by researchers at the University of Minnesota Medical School. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Eating less sugar could protect the microbiome during antibiotic treatment, according to a study led by researchers at City of Hope. The study followed patients with blood cancer who were going through an intensive treatment called allogeneic hematopoietic cell transplant. This population is at particularly high risk for severe gut microbiome disruption and associated side effects. 
Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login